Posts tagged “GSK”

July 13

G1 Therapeutics names former GSK top exec Andrew Witty to board

Andrew Witty, formerly CEO of drug giant GlaxoSmithKline, is now a member of the board of directors at RTP-based G1 Therapeutics.

Andrew Witty         Andrew Witty

July 3

Premium Lock GSK turns to AI to speed up drug development, invests $43M in startup

GSK in Zebulon     GlaxoSmithKline sees the potential of using artificial intelligence to boost drug development. And its latest investment in a startup reflects that commitment. Plus: A profile of the GSK-backed startup.

June 20

Premium Lock In a short filing, GSK confirms deal for new pharma CEO

GSK's HQ in London               GlaxoSmithKline will have a new head of pharmaceutical operations as of Sept. 4 after settling a dispute with rival AstraZeneca over the poaching of one of its top executives.

May 30

Premium Lock New $80M look for GSK's Triangle campus coming under ownership change

Glaxo Smith Kline's sprawling campus in Research Triangle Park is heading toward a major remodeling under new owner Parmer Innovation, which is promising "one of the most influential amenity parks in the Southeast."

GSK leases Charles Sanders center GSK leases Charles Sanders center

Updated April 26

Premium Lock GSK revenues surge yet generic drugs pose big threat

GlaxoSmithKline says new products helped first-quarter sales rise 17 percent from the year before but warned that competition from generic drugs may weigh on earnings later this year.

Updated April 25

Premium Lock Dish unveils $999 system to make live online video easier (+ video)

Dish, a company known largely for its old-school satellite TV, is now trying to make it easier for people to stream quality video live over YouTube and Facebook.

Updated March 15

Premium Lock GSK will pay first female CEO 25% less than Andrew Witty

GlaxoSmithKline says in its annual report that it will pay incoming CEO Emma Walmsley - the first woman to lead a top drug maker - some 25 percent less than the man she is replacing.

March 15

Premium Lock Couple sue GlaxoSmithKline for work that led to prison in China

Peter Humphrey and Yu Yingzeng, back in Britain with health problems and in financial ruin, are now suing GSK for allegedly misleading them on what the job was about and exposing them to legal risks in China they could not have foreseen. GSK says there's no merit to the claim.

Peter Humphrey Peter Humphrey

Updated January 19

Premium Lock GSK pharma chief to quit after losing out on CEO job

GSK's HQ in London               GlaxoSmithKline's head of pharmaceuticals is leaving the drug giant after losing out in the race to replace retiring CEO Andrew Witty. GSK is hiring an AstraZeneca exec to replace him.

December 20, 2016

Premium Lock GSK launches trial for long-acting injection to prevent HIV

HIV AIDS research   GlaxoSmithKline's ViiV Healthcare is launching a phase 3 clinical trial of a long-lasting injection that could prevent the HIV virus.

December 5, 2016

Premium Lock GSK names new leader for ViiV Healthcare

ViiV Healthcare Dr. Dominique Limet is leaving after seven years as the CEO of GSK-owned ViiV Healthcare, which focuses on treatments for HIV. He will be replaced by GSK executive Deborah Waterhouse.

November 18, 2016

Premium Lock GSK awards $400,000 to Triangle nonprofits

GSK in Zebulon     GlaxoSmithKline hands out $400,000 in grants to 10 Triangle area nonprofits as part of its GSK Impact Awards.

Tags: GSK
October 24, 2016

Premium Lock Got a cough? GSK adding IBM's Watson to help you find answers

IBM Watson avatar     As WRAL TechWire has reported extensively over the past few months, IBM keeps adding to the capabilities of its Watson supercomputer services. Now, drug giant GSK is incorporating Watson interactive artificial intelligence into an advertising campaign for its cough and cold advertising.

October 24, 2016

Premium Lock GSK seeks US approval for blockbuster shingles vaccine

GSK's HQ in London               GlaxoSmithKline is seeking FDA approval for its new shingles vaccine, a drug that analysts say could be a $1 billion-a-year blockbuster.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith